Trial Profile
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Dinutuximab (Primary) ; Irinotecan; Topotecan
- Indications Carcinoma; Small cell lung cancer
- Focus Therapeutic Use
- Acronyms DISTINCT
- Sponsors United Therapeutics Corporation
- 01 Apr 2022 Results published in the Lung Cancer
- 31 May 2020 Exploratory analyses of this study to evaluate GD2 expression in circulating tumor cells, select protein biomarkers, and any correlative impact on observed response are ongoing as per the results presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 31 May 2020 Results from part II portion, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.